*September 2021*
Discussing the case for antibody drug conjugate (ADC) or tyrosine kinase inhibitor TKI for HER2 mutated lung cancer at ESMO 2021:
We are a group of lung cancer patients with EGFR mutations who have developed resistance to at least one targeted treatment drug, or who face probable resistance in the future. Caregivers are also welcome. We are here to share treatment experiences, information about clinical trials, breaking news about research developments, and other information with each other.